|
|
|
|
|
|
by 15155
162 days ago
|
|
|
> Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years. So they are good stewards of their funds and know they can't deploy as much as they have? Berkshire Hathaway does the same thing. |
|
|